BALPHARMA.NSBALPHARMA.NSNSE
Loading
EBITDA Margin Over TimeStrong
Percentile Rank67
3Y CAGR+8.6%
5Y CAGR-0.3%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+8.6%/yr
vs -0.8%/yr prior
5Y CAGR
-0.3%/yr
Recent acceleration
Acceleration
+9.3pp
Accelerating
Percentile
P67
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
TTM10.31%-1.6%
202510.48%+11.0%
20249.44%+17.2%
20238.05%-5.5%
20228.52%-18.4%
202110.44%+265.5%
20202.86%-65.6%
20198.31%-8.1%
20189.04%+16.0%
20177.80%-